Emma Iserman
YOU?
Author Swipe
View article: Comparative safety of drug therapies used in hemophilia A and B in Canada: a multi-center, retrospective study
Comparative safety of drug therapies used in hemophilia A and B in Canada: a multi-center, retrospective study Open
View article: Feasibility of Administering the Patient Reported Outcomes, Burdens and Experiences (PROBE) Questionnaire Through the Canadian Bleeding Disorders Registry (CBDR) and Comparison of Data From the Two Sources
Feasibility of Administering the Patient Reported Outcomes, Burdens and Experiences (PROBE) Questionnaire Through the Canadian Bleeding Disorders Registry (CBDR) and Comparison of Data From the Two Sources Open
Introduction The Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire can be used to measure quality of life in persons with haemophilia (PWH) and is integrated in the Canadian Bleeding Disorders Registry (CBDR). This o…
View article: Exploring the Impact of Laboratory Reagents on Pharmacokinetic Profiling
Exploring the Impact of Laboratory Reagents on Pharmacokinetic Profiling Open
Background Laboratory reagents impact measured factor activity of extended half‐life (EHL) concentrates. Variability in measurements may lead to under or over estimation of the pharmacokinetic (PK) parameters, and thus influence clinical d…
View article: Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada
Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada Open
Introduction Damoctocog alfa pegol (BAY 94–9027, Jivi®) is an extended half‐life recombinant factor (F)VIII replacement, indicated for the treatment of haemophilia A in patients aged ≥12 years. Following introduction of damoctocog alfa peg…
View article: OC 24.1 Effect of the Type of F9 Mutation on the Pharmacokinetic Profile of Patients with Hemophilia B Treated with Extended Half-Life FIX Concentrates
OC 24.1 Effect of the Type of F9 Mutation on the Pharmacokinetic Profile of Patients with Hemophilia B Treated with Extended Half-Life FIX Concentrates Open
deviation) number of injections for bleed treatment was 1.8 (5.10) pre-study versus 1.1 (0.30) on-study.Mean (95% CI) change in weekly injection frequency and consumption was -1.37 (-1.59, -1.15) doses and -35.00 (-47.82,-22.18)IU/kg, resp…
View article: PB0644 Evaluation of the Burden of Bone Fractures in People Living with Hemophilia: A Registry-Based Case-Control Study
PB0644 Evaluation of the Burden of Bone Fractures in People Living with Hemophilia: A Registry-Based Case-Control Study Open
bleeding rate.
View article: PB0175 Impact of Reagent on the Estimation of Eloctate and Adynovate Pharmacokinetic (PK) Parameters?
PB0175 Impact of Reagent on the Estimation of Eloctate and Adynovate Pharmacokinetic (PK) Parameters? Open
View article: OC 24.2 Estimated Factor VIII Activity Levels at the Time of Bleeding Events in Individuals with Hemophilia a Without Inhibitors
OC 24.2 Estimated Factor VIII Activity Levels at the Time of Bleeding Events in Individuals with Hemophilia a Without Inhibitors Open
View article: Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes
Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes Open
N9-GP improves clinical outcomes and may be cost-saving vs nonacog alfa and eftrenonacog alfa.
View article: Reflections on the Canadian Bleeding Disorders Registry: Lessons Learned and Future Perspectives
Reflections on the Canadian Bleeding Disorders Registry: Lessons Learned and Future Perspectives Open
The Canadian Bleeding Disorders Registry (CBDR) has become the national registry for comprehensive care and research in hemophilia in Canada with patient, clinical, and research module connectivity.
The CBDR has served as a robust resou…
View article: Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia
Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia Open
Predicting individual effects of switching from standard half-life (SHL) to extended half-life (EHL) FVIII/FIX concentrates is pivotal in clinical care, but large-scale individual data are scarce. The aim of this study was to assess indivi…
View article: Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study
Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study Open
View article: Terminal half‐life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database
Terminal half‐life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database Open
View article: Terminal Half-Life of Factor VIII/IX According to Age and Blood Group Based on 8550 Assessments
Terminal Half-Life of Factor VIII/IX According to Age and Blood Group Based on 8550 Assessments Open
Introduction: Extended half-life concentrates were recently introduced and limited data have shown extended terminal half-life (THL). However, real-life data on pharmacokinetics in large cohorts of patients with haemophilia (PWH) and infor…
View article: Methods for trials of interventions to enhance patient adherence to medication prescriptions, based on a systematic review of recent randomized trials
Methods for trials of interventions to enhance patient adherence to medication prescriptions, based on a systematic review of recent randomized trials Open
Background: Low patient adherence to prescribed medications is very common and likely the most important barrier to the implementation of effective health care.Controlled trials of interventions to improve adherence have not found consiste…